REGAL Enrollment Slows, Cash Dips to $107M, Takeover Chatter Emerges
SLS has more than doubled off its 52-week low of $1.39.
Summary
The pivotal Phase 3 REGAL trial is enrolling slower than expected, which the company attributes to a potentially durable GPS treatment effect—a double-edged signal that could mean stronger efficacy but delays the final data readout. Cash has dipped to $107.1M from $114.7M pro forma in May, partly offset by $28.7M in warrant exercises, while executive severance terms were updated in late June. New takeover chatter is surfacing, with traders linking big pharma interest to the timing of the final analysis. The 80th event trigger will be announced before topline results, followed by a quiet period. This follows the May 10-Q that highlighted the trial nearing completion and the June 8-K on warrant proceeds. The enrollment slowdown and M&A speculation add fresh uncertainty to the timeline and valuation.
At the time of this announcement, SLS was trading at $13.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $1.39 to $15.88. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.